We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


BioWa Announces Extended Licensing to MedImmune of BioWa's POTELLIGENT® Technology

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioWa Announces Extended Licensing to MedImmune of BioWa's POTELLIGENT® Technology"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

BioWa, Inc. has announced that it has entered into a second agreement with MedImmune to provide additional access to BioWa's patented POTELLIGENT® Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.

The agreement grants to MedImmune non-exclusive license rights to develop, manufacture and market antibodies based on POTELLIGENT® Technology for an undisclosed number of targets. In return, BioWa receives from MedImmune certain fees and milestone payments during product development, as well as royalties on marketed products using ADCC enhanced antibodies.

"We are pleased to extend our relationship with MedImmune, a world-leading biologics business and the cornerstone to AstraZeneca's plans to establish a major international presence in the research and development of biological therapeutics," said Dr. Masamichi Koike, President and CEO of BioWa. "With MedImmune's superior expertise in antibody-based drug development, this collaboration complements BioWa's mission to bring about the benefit of POTELLIGENT® Technology to patients as quickly as possible."